Highly efficient biosynthesis of 2,4-dihydroxybutyric acid by a methanol assimilation pathway in engineered Escherichia coli

被引:5
|
作者
Dong, Xianjuan [1 ]
Sun, Chao [1 ,2 ,3 ]
Guo, Jing [1 ,2 ,3 ]
Ma, Xiangyu [1 ,4 ]
Xian, Mo [1 ,2 ,3 ]
Zhang, Rubing [1 ,2 ,3 ]
机构
[1] Chinese Acad Sci, Qingdao Inst Bioenergy & Bioproc Technol, CAS Key Lab Biobased Mat, Qingdao 266101, Peoples R China
[2] Shandong Energy Inst, Qingdao 266101, Peoples R China
[3] Qingdao New Energy Shandong Lab, Qingdao 266101, Peoples R China
[4] Univ Chinese Acad Sci, Beijing 100049, Peoples R China
基金
中国国家自然科学基金;
关键词
ALDO-KETO REDUCTASES; METABOLIC PATHWAY; DEHYDROGENASE; METHYLOTROPHY; PROTEIN; EVOLUTION; BIOFUELS; MALATE; GROWTH; OIL;
D O I
10.1039/d3gc02083e
中图分类号
O6 [化学];
学科分类号
0703 ;
摘要
2,4-Dihydroxybutyric acid (2,4-DHB) is an important fine chemical, which can be used as a precursor in the production of important chemicals. Methanol, as an attractive C1 compound, is an ideal nonfood sugar feedstock for biomanufacturing. In this study, we reported for the first time the biosynthesis of 2,4-DHB in engineered Escherichia coli from a mixture of methanol and glucose. In this process, methanol dehydrogenase was used to convert methanol into formaldehyde, and the key intermediate 2-keto-4-hydroxybutyric acid was synthesized through the condensation of formaldehyde and pyruvate derived from glycolysis by pyruvate-dependent aldolase, which was subsequently transformed into the target product 2,4-DHB by an enzymatic hydrogenation reaction. The new pathway demonstrated the feasibility of producing 2,4-DHB from methanol and glucose in E. coli. For improving the production of 2,4-DHB step by step, dehydrogenases and aldo-keto reductases with higher activity towards 2,4-DHB were screened, and the pyruvate degradation pathway genes were knocked out to enhance the flux from pyruvate towards 2,4-DHB biosynthesis, resulting in the strain DHB9 with about 10-fold improvement compared to the initial strain DHB4. Additionally, the methanol dehydrogenase MDHCn with higher enzymatic activity was obtained by screening. The mutant MDHCn (G48F) with improved activity in vitro was obtained by rational analysis of MDHCn, and the results showed that the enzymatic activity of MDHCn (G48F) increased 3-fold in vitro compared with that of the wild type. Finally, on the basis of the above work, the best engineered strain DHB13 was constructed by knocking out the gene (frmRAB) responsible for the conversion of formaldehyde to formic acid, and the target product 2,4-DHB was accumulated up to 14.6 g L-1 in a 5 L bioreactor. To date, the highest concentration of 2,4-DHB has been achieved in this work, which is promising to make the bioprocess feasible from an economic perspective. Moreover, one glucose molecule and two methanol molecules can be bio-transformed into two 2,4-DHB molecules with 100% conversion of carbon atoms in theory, showing the high carbon atom economy of the novel synthetic metabolic pathway.
引用
收藏
页码:7662 / 7672
页数:11
相关论文
共 50 条
  • [1] Enhanced biosynthesis of 3,4-dihydroxybutyric acid by engineered Escherichia coli in a dual-substrate system
    Gao, Haijun
    Gao, Yu
    Dong, Runan
    BIORESOURCE TECHNOLOGY, 2017, 245 : 794 - 800
  • [2] Construction of a synthetic metabolic pathway for biosynthesis of 2,4-dihydroxybutyric acid from ethylene glycol
    Frazao, Claudio J. R.
    Wagner, Nils
    Rabe, Kenny
    Walther, Thomas
    NATURE COMMUNICATIONS, 2023, 14 (01)
  • [3] Construction of a synthetic metabolic pathway for biosynthesis of 2,4-dihydroxybutyric acid from ethylene glycol
    Cláudio J. R. Frazão
    Nils Wagner
    Kenny Rabe
    Thomas Walther
    Nature Communications, 14 (1)
  • [4] Modification of an engineered Escherichia coli by a combinatorial strategy to improve 3,4-dihydroxybutyric acid production
    Yidi Liu
    Xinlei Mao
    Baoqi Zhang
    Jinping Lin
    Dongzhi Wei
    Biotechnology Letters, 2021, 43 : 2035 - 2043
  • [5] Construction of a synthetic metabolic pathway for biosynthesis of the non-natural methionine precursor 2,4-dihydroxybutyric acid
    Thomas Walther
    Christopher M. Topham
    Romain Irague
    Clément Auriol
    Audrey Baylac
    Hélène Cordier
    Clémentine Dressaire
    Luce Lozano-Huguet
    Nathalie Tarrat
    Nelly Martineau
    Marion Stodel
    Yannick Malbert
    Marc Maestracci
    Robert Huet
    Isabelle André
    Magali Remaud-Siméon
    Jean Marie François
    Nature Communications, 8
  • [6] Modification of an engineered Escherichia coli by a combinatorial strategy to improve 3,4-dihydroxybutyric acid production
    Liu, Yidi
    Mao, Xinlei
    Zhang, Baoqi
    Lin, Jinping
    Wei, Dongzhi
    BIOTECHNOLOGY LETTERS, 2021, 43 (10) : 2035 - 2043
  • [7] Construction of a synthetic metabolic pathway for biosynthesis of the non-natural methionine precursor 2,4-dihydroxybutyric acid
    Walther, Thomas
    Topham, Christopher M.
    Irague, Romain
    Auriol, Clement
    Baylac, Audrey
    Cordier, Helene
    Dressaire, Clementine
    Lozano-Huguet, Luce
    Tarrat, Nathalie
    Martineau, Nelly
    Stodel, Marion
    Malbert, Yannick
    Maestracci, Marc
    Huet, Robert
    Andre, Isabelle
    Remaud-Simeon, Magali
    Francois, Jean Marie
    NATURE COMMUNICATIONS, 2017, 8
  • [8] Construction of a synthetic metabolic pathway for the production of 2,4-dihydroxybutyric acid from homoserine
    Walther, Thomas
    Calvayrac, Florence
    Malbert, Yoann
    Alkim, Ceren
    Dressaire, Clementine
    Cordier, Helene
    Francois, Jean Marie
    METABOLIC ENGINEERING, 2018, 45 : 237 - 245
  • [9] Establishing a novel biosynthetic pathway for the production of 3,4-dihydroxybutyric acid from xylose in Escherichia coli
    Wang, Jia
    Shen, Xiaolin
    Jain, Rachit
    Wang, Jian
    Yuan, Qipeng
    Yan, Yajun
    METABOLIC ENGINEERING, 2017, 41 : 39 - 45
  • [10] Cofactor engineering for improved production of 2,4-dihydroxybutyric acid via the synthetic homoserine pathway
    Ihle, Nadine
    Gruessner, Laura
    Alkim, Ceren
    Nguyen, T. A. Stefanie
    Walther, Thomas
    Frazao, Claudio J. R.
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2025, 13